Functional precision medicine approaches may complement current paradigms for non-metastatic colorectal cancer management.
This commentary addresses the management of patients with non-metastatic colorectal cancer, focusing on the limitations of current treatment paradigms and the potential utility of functional precision medicine approaches. The authors utilize hypothetical patient journeys and illustrative examples drawn from a retrospective cohort to explore these concepts. The text highlights that current practice often fails to align with patient needs despite being guideline-concordant, specifically regarding inter-patient and intra-tumoral heterogeneity that contributes to treatment resistance, recurrence, and unnecessary toxicity.
The discussion centers on functional precision medicine approaches, including genomic profiling and ex vivo drug responses, as potential tools to refine therapy selection and improve surveillance strategies. The commentary suggests that these methods can aid in the identification of intra-patient heterogeneity and differential drug sensitivity, thereby facilitating therapeutic stratification. However, the authors emphasize that guideline-concordant care remains necessary, even if it is not sufficient for all patients.
No specific adverse events, serious adverse events, discontinuations, or tolerability data were reported, as the study is a commentary rather than a clinical trial. Key limitations include the shortcomings of modern tools such as genomic profiling and the inherent constraints of current treatment paradigms. The authors caution that while functional precision medicine approaches have the potential to complement existing treatment paradigms, they are not definitive solutions. Continued research efforts are required to validate these technologies before they can be fully integrated into standard practice.